Cipla Share Price
(CIPLA)
₹1463.35
as on 04:01PM, 25 Feb 2025
Cipla Performance
Day's Low
Day's High
₹1,454.6Day's Price Range₹1,482.452 Week's Low
52 Week's High
₹1,317.2552-Week Price Range₹1,702.05
| Returns % | |
| 1 Month Return | + 4.82 % |
| 3 Month Return | -1.97 % |
| 1 Year Return | -0.44 % |
| Market Stats | |
| Previous Close | ₹1,476.75 |
| Open | ₹1,471.00 |
| Volume | 9.93L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,18,182.20Cr |
Cipla Key Statistics
P/E Ratio
23.68
PEG Ratio
1.49
Market Cap
₹1,18,182.20 Cr
P/B Ratio
4.31
EPS
51.47
Dividend Yield
0.87
Sector
Pharmaceuticals
ROE
15.5
Cipla Mutual Fund Holdings
Cipla Analyst Rating
based on 37 analysts
64.86%
Buy
21.62%
Hold
13.51%
Sell
Based on 37 analysts offering long term price targets for Cipla. An average target of ₹1644.19
Source: S&P Global Market Intelligence
Cipla Share analysis
Cipla price forecast by 37 analysts
Upside of12.36%
High
₹1875
Target
₹1644.19
Low
₹1204
Cipla target price ₹1644.19, a slight upside of 12.36% compared to current price of ₹1463.35. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cipla revenue growth forecast
Expected growth rate Q1, FY2027:24.66%
Forecast
Actual
Including amortisation and stock based compensations
Cipla EPS growth forecast
EPS estimate Q1, FY2027:30.23%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Cipla Ltd
Cipla Remains Confident Amid US Tariffs - 26 Feb, 2025
Cipla's CEO, Umang Vohra, asserts that US tariffs won't hinder Indian generics' competitiveness. He is optimistic about growth opportunities in GLP-1 and semaglutide, with Nomura maintaining a Buy rating and a target price of Rs 1,780, indicating a 22% upside.Cipla Receives USFDA Approval for Nilotinib Capsules - 20 Feb, 2025
Cipla Limited has received final USFDA approval for Nilotinib Capsules (50, 150, and 200 mg), a significant advancement in treating chronic myeloid leukemia. The launch is planned for FY 2025-26.Cipla Faces Market Challenges Amid Investment News - 19 Feb, 2025
Cipla Ltd's stock faced volatility with a significant drop in share price, potential earnings impact from export duties, and a new investment in South Africa. A market expert issued a buy recommendation.Positive Recommendations and Guidance for Cipla Shares - 18 Feb, 2025
Cipla received a buy recommendation from market expert Nooresh Merani, targeting Rs 1600. The company also revised its guidance upwards to 25.5%.Cipla Faces Challenges Amid Weak US Market Outlook - 14 Feb, 2025
Analyst Manchanda suggests Cipla may be less affected by market changes, but FY27 could be challenging due to anticipated weakness in the US business for major pharma companies.Cipla Reports Strong Growth and Market Position - 11 Feb, 2025
Cipla Ltd, a leading player in the Indian Rx market, reports substantial growth in sales and net profit, with a market cap of Rs 1,18,703 cr. The company aims for a 20% CAGR until 2030, positioning itself as the second-largest pharma company in India.Cipla Shares Decline After USFDA VAI Classification - 10 Feb, 2025
Cipla shares fell nearly 3% following the USFDA's VAI classification of its Bengaluru facility inspection. Despite this, Cipla reported strong earnings and plans significant investments in South Africa.Cipla's Facility Receives USFDA VAI Status - 08 Feb, 2025
Cipla Limited's manufacturing facility in Virgonagar has been classified as Voluntary Action Indicated by the USFDA. The company reported strong Q3 FY25 results, with revenue of ₹7,073 crore and a net profit increase of 50% year-on-year.Cipla Invests in South African Subsidiary for Growth - 03 Feb, 2025
Cipla Ltd plans to infuse approximately ZAR 900 million (around Rs 415 crore) into its South African subsidiary, Cipla Medpro, to reduce inter-group debt and enhance its capital structure. The investment is expected to be completed by February 28, 2025.Cipla Stock to Benefit from Budget Announcements - 01 Feb, 2025
Following the budget announcement, pharmaceutical stocks, including Cipla, are expected to remain in focus due to potential changes in tariffs and incentives.Cipla Stock Gains on Positive Financial Outlook - 31 Jan, 2025
Cipla's stock rose by 3% as analysts maintain positive ratings, with Prabhudas Lilladher setting a target of Rs 1,730 and KR Choksey at Rs 1,598. The company's participation in a PLI for anti-diabetic medications is also seen as a positive development.Cipla Maintains Buy Rating with Target Price of Rs 1730 - 30 Jan, 2025
Prabhudas Lilladher maintains a 'BUY' rating on Cipla with a target price of Rs 1730. Q3FY25 results exceeded estimates, driven by strong India sales and margin improvements. Despite some delays in key launches, Cipla's strong cash position and upcoming high-value product launches in FY26E/27E are expected to support growth.Cipla Reports Strong Q3 Earnings, Shares Surge - 28 Jan, 2025
Cipla Ltd reported a robust Q3 FY25 with a 49% increase in net profit to ₹1,571 crore and revenue of ₹7,073 crore, exceeding estimates. The company expects to surpass its margin guidance, driven by strong sales in India and Europe despite challenges in the US market.
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 1 month, CIPLA stock has moved up by 4.8%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 939.04 Cr → 1.57K Cr (in ₹), with an average increase of 15.6% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 6.41K Cr → 7.29K Cr (in ₹), with an average increase of 4.2% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 17.44% to 20.42% in Dec 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 16.08% to 16.41% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 120.5% return, outperforming this stock by 62.3%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 60.1% return, outperforming this stock by 60.5%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 30.86% to 29.13% in Dec 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 28.74% to 26.60% in Dec 2024 quarter
News
Cipla Confident on US Tariffs Impact on Indian Generics
The Managing Director and CEO of Cipla, Umang Vohra is confident that tariffs and regulations in the US will not impact the competitiveness of Indian generics and are a long-term positive for the Indian pharma sector. He reiterated that, Indian generics industry will remain intact even if US imposes tariffs. This was during a conversation with international brokerage house Nomura where they touched upon various issues that are impacting the sector and Cipla. In the note that Nomura shared based on the key takeaways from the conversation, Vohra highlighted that he is positive on the GLP-1 and semaglutide opportunity in India as Cipla prepares to participate in the first wave. According to Nomura, the oral formulation also presents a high-value opportunity for companies that overcome the IP and regulatory barriers. Vohra expects Cipla to sustain current earnings or grow them marginally post gRevlimid and doesnt expect a steep fall. Nomura pointed out that the comments are largely aligned with our expectations. We have a Buy rating on the stock with a March 2026 target price of Rs 1,780. This implies 22% upside from the current levels. The Nomura price target is based on 28.5x FY27 EPS expectation of Rs 62.30. The brokerage expects FY25 EPS at Rs 62.90 while for FY26 it is seen at Rs 60.90.26 Feb, 2025 09:45 AMImpact of Trump's Tariffs on Indian Pharma Companies
According to an HSBC report, a 10 percent tariff on pharma imports could impact the earnings of Indian pharma companies, with Cipla seeing a 4 percent reduction in its earnings per share (EPS).25 Feb, 2025 12:53 AMTrump's Tariff Threats Shake Up India's Pharmaceutical Export Hopes
Key players like Sun Pharmaceuticals, Dr. Reddys Laboratories, and Cipla rely heavily on the U.S. market, contributing a substantial portion of their revenue. If tariffs proceed, companies anticipate passing costs onto consumers, potentially affecting drug prices and U.S. healthcare dynamics.21 Feb, 2025 05:27 PMCipla Financials
Index Inclusions
Cipla Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 29.13% | ||
| Foreign Institutions | 26.6% | ||
| Mutual Funds | 20.42% | 17.09 | |
| Retail Investors | 16.41% | 2.06 | |
| Others | 7.44% | 8.01 |
Cipla Key Indicators
Cipla Valuation
Cipla in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (23.68x)
February 25, 2025
Industry (50.89x)
February 25, 2025
Highest (42.80x)
January 23, 2018
Cipla Earnings and Dividends
Cipla Ltd Earnings Results
Cipla Ltd’s net profit jumped 48.74% since last year same period to ₹1,570.51Cr in the Q3 2024-2025. On a quarterly growth basis, Cipla Ltd has generated 20.57% jump in its net profits since last 3-months.
Read More about Earnings ResultsCipla Ltd Dividends May,2024
In the quarter ending March 2024, Cipla Ltd has declared dividend of ₹13 - translating a dividend yield of 1.47%.
Read More about Dividends
Cipla Technicals Summary
Bearish
Neutral
Bullish
Cipla Ltd is currently in a Bearish trading position according to technical analysis indicators.
Cipla Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹1,18,182.20 Cr | 49.32% | 0.50 | ₹4,155 Cr | ₹25,774 Cr | |
| HOLD | ₹1,52,017.93 Cr | 33.47% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,02,579.90 Cr | 33.86% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹38,563.27 Cr | 1.5% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹26,325.68 Cr | -2.44% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Cipla
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Share Price: ₹1463.35 per share as on 25 Feb, 2025 04:01 PM
Market Capitalisation: ₹1,18,182.20Cr as of today
Revenue: ₹6,961.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,583.72Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Cipla Ltd
What is Cipla Ltd price today?
Cipla Ltd share price today stands at ₹1463.35, Open: ₹1471, Previous Close: ₹1476.75, High: ₹1482.4, Low: ₹1454.6, 52 Week High: ₹1702.05, 52 Week Low: ₹1317.25.
How to Buy Cipla Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Cipla Ltd shares
Is Cipla Ltd listed on NSE?
Cipla Ltd is listed on NSE
Is Cipla Ltd listed on BSE?
Cipla Ltd is listed on BSE
What are today's High and Low prices of Cipla Ltd?
- Today's highest price of Cipla Ltd is ₹1482.4.
- Today's lowest price of Cipla Ltd is ₹1454.6.
What are today's traded volumes of Cipla Ltd?
Today's traded volume of Cipla Ltd(CIPLA) is 9.93L.
What is today's market capitalisation of Cipla Ltd?
Today's market capitalisation of Cipla Ltd(CIPLA) is ₹118182.2Cr.
What is the 52 Week High and Low Range of Cipla Ltd?
How much percentage Cipla Ltd is down from its 52 Week High?
Cipla Ltd (CIPLA) share price is ₹1463.35. It is down -14.02% from its 52 Week High price of ₹1702.05
How much percentage Cipla Ltd is up from its 52 Week low?
Cipla Ltd (CIPLA) share price is ₹1463.35. It is up 11.09% from its 52 Week Low price of ₹1317.25
What are the historical returns of Cipla Ltd?
What is the PE ratio of Cipla Ltd today?
PE Ratio of Cipla Ltd is 23.68
PE ratio = Cipla Ltd Market price per share / Cipla Ltd Earnings per share